PET/CT

Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.

PET method offers new insight into inflammation of the brain
Researchers are hopeful that their technique could improve the diagnosis of conditions associated with neural inflammation.
New PET imaging method could improve our understanding of long COVID
Researchers have developed a new radiotracer that targets one of the virus’ spike proteins, allowing them to track it longitudinally.
FDA approves new prostate cancer imaging agent with extended shelf life
The new product from Telix paves the way for increased access at clinics where prostate PET may not have been available in the past.
New PET study offers insight into how dopamine drives executive function
These findings could help guide the development of new treatments for psychiatric and neurological disorders.
Bracco updates HeartSee coronary flow capacity software with new diagnostic features
Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

FDA clears spinal-tap test that could challenge PET in Alzheimer’s diagnostics

The FDA has approved a lab test for evaluating cognitively impaired adults who may be in the early stages of Alzheimer’s disease.

CMS coverage decision for Alzheimer's drug, related PET scans sparks concern in imaging community

In a statement released on April 14, MITA cautioned that the coverage decision will “severely limit patient access” to amyloid PET diagnostics and anti-amyloid monoclonal antibodies treatment.

coronavirus COVID-19 vaccine vaccination

FDG PET/CT radiomics distinguishes between vaccine-related or metastatic breast cancer lymphadenopathy

The findings could help clinicians manage patients’ treatment when the origin of axillary lymphadenopathy is of concern, experts suggested.

Combination therapy that includes new radionuclide proves effective for metastatic prostate cancer

The therapeutic combination of 177Lu-PSMA-617 with idronoxil (NOX66) reduced PSA levels in 86% of study participants.

MRI/PET scans link brainstem atrophy to dementia symptoms

Experts suggest that their findings could help differentiate between dementia and other neurological diseases that have similar symptoms.

New radiotracer that detects prostate cancer recurrence produces 'stunning' results

The research focused on a radiopharmaceutical that contains the isotope zirconium 89, which has a significantly longer half-life compared to gallium-68-labelled PSMA ligands.

PET scans spot brain abnormalities in long COVID patients

For 47% of patients with long COVID symptoms, brain PET scans identified mild to moderate or severe hypometabolic patterns.

FDA approves new radioligand therapy for PSMA positive metastatic prostate cancer

In clinical trials, the therapy reduced patients' risk of death by 38%, along with significantly decreasing disease progression.

PET/CT

PET method offers new insight into inflammation of the brain

New PET imaging method could improve our understanding of long COVID

FDA approves new prostate cancer imaging agent with extended shelf life

New PET study offers insight into how dopamine drives executive function

Bracco updates HeartSee coronary flow capacity software with new diagnostic features